Browsing restrictions can be lifted for a fee.
Aplus Biotechnology Corporation Limited engages in the development of orthopedic trauma medical equipment products. The company is based in New Taipei City, Taiwan.
6918
愛派司
-1.71%
(-0.02)
The most recent financial report for 愛派司 (6918) covers the period of 2025Q3 and was published on 2025/09/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 6918's short-term business performance and financial health. For the latest updates on 6918's earnings releases, visit this page regularly.
According to historical valuation range analysis, 愛派司 (6918)'s current price-to-earnings (P/E) ratio is 14.66, placing it in the Value zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.
According to the latest financial report, 愛派司 (6918) reported an Operating Profit of 48.77M with an Operating Margin of 23.15% this period, representing a growth of 7.73% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
In the latest financial report, 愛派司 (6918) announced revenue of 210.7M, with a Year-Over-Year growth rate of 5.21%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
At the end of the period, 愛派司 (6918) held Total Cash and Cash Equivalents of 488.92M, accounting for 0.32 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 愛派司 (6918) achieved the “three margins increasing” benchmark, with a gross margin of 68.56%%, operating margin of 23.15%%, and net margin of 20.66%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 6918's profit trajectory and future growth potential.
According to the past four quarterly reports, 愛派司 (6918)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.26. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.